Scholar Rock Holding Corporation (SRRK) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Scholar Rock Holding Corporation (SRRK) Healthcare & Pipeline Overview

Scholar Rock Holding Corporation is a biopharmaceutical firm specializing in growth factor-targeted therapies for diseases like spinal muscular atrophy and cancer. Their lead drug, Apitegromab, is in late-stage development, positioning them as a potential player in neuromuscular disorders. They also have a collaboration with Gilead Sciences.

What Is the Investment Thesis for SRRK?

Scholar Rock's investment thesis hinges on the success of Apitegromab in treating spinal muscular atrophy and the potential of SRK-181 in overcoming resistance to cancer immunotherapies. Apitegromab's Phase 3 trial results will be crucial in determining its market viability. Positive outcomes could lead to significant revenue generation, given the unmet need in SMA treatment. The company's collaboration with Gilead Sciences for fibrosis treatments adds another layer of potential value. However, the biotechnology sector is inherently risky, with clinical trial failures and regulatory hurdles posing significant challenges. The company's ability to secure regulatory approvals and commercialize its products will be critical to its long-term success. As of 2026, the company's market capitalization is $5.67 billion.

Based on FMP financials and quantitative analysis

SRRK Key Highlights

• Apitegromab completed Phase 3 clinical trials for spinal muscular atrophy, indicating potential for near-term revenue generation pending regulatory approval.
• SRK-181 is in Phase 1 clinical trials for cancers resistant to checkpoint inhibitor therapies, representing a potential expansion into the oncology market.
• Collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases diversifies the pipeline.
• The company was founded in 2012, indicating a relatively young but focused approach to biopharmaceutical development.
• The company's focus on growth factor biology provides a targeted approach to addressing serious diseases.

Who Are SRRK's Competitors?

SRRK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SRRK's Key Strengths?

• Proprietary technology platform targeting growth factors
• Clinical-stage lead product candidate (Apitegromab)
• Collaboration with Gilead Sciences
• Experienced management team

What Are SRRK's Weaknesses?

• Reliance on clinical trial outcomes
• Limited commercialization experience
• High cash burn rate
• Competition from established pharmaceutical companies

What Could Drive SRRK Stock Higher?

• Apitegromab Phase 3 trial data readout in SMA (2026)
• SRK-181 Phase 1 trial results in cancer (2027)
• Potential for new strategic collaborations (2026-2027)
• Regulatory submissions for Apitegromab (2027)

What Are the Key Risks for SRRK?

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for Apitegromab or SRK-181
• Regulatory delays or rejection of Apitegromab
• Competition from other SMA therapies
• Dependence on key personnel
• Intellectual property challenges

What Are the Growth Opportunities for SRRK?

• Expansion of Apitegromab into additional SMA patient populations: Apitegromab is currently being evaluated for specific SMA subtypes. Expanding its use to broader SMA populations could significantly increase its market potential. The global market for SMA therapeutics is projected to reach $2.5 billion by 2028, presenting a substantial opportunity for Scholar Rock if Apitegromab proves effective across different patient groups. This expansion hinges on further clinical trials and regulatory approvals, with potential timelines spanning from 2027 to 2030.
• Advancement of SRK-181 in oncology: SRK-181 targets cancers resistant to checkpoint inhibitors, a growing area of unmet need in oncology. Successful Phase 2 and Phase 3 trials could position SRK-181 as a valuable addition to cancer treatment regimens. The market for checkpoint inhibitor therapies is estimated to exceed $40 billion by 2027, and overcoming resistance to these therapies represents a significant growth opportunity for Scholar Rock. This advancement depends on clinical trial outcomes and regulatory approvals, with potential timelines extending from 2028 to 2032.
• Development of novel therapies for fibrosis: The collaboration with Gilead Sciences to develop inhibitors of transforming growth factor beta activation for fibrotic diseases represents a strategic growth opportunity. Fibrosis affects various organs, and effective treatments are limited. The market for antifibrotic therapies is projected to reach $15 billion by 2028, offering a substantial revenue potential for Scholar Rock. This development is contingent on successful drug discovery and clinical trials, with timelines potentially extending from 2029 to 2033.
• Strategic partnerships and collaborations: Scholar Rock can leverage strategic partnerships and collaborations to expand its pipeline and access new technologies. Collaborating with other biotech or pharmaceutical companies can provide access to complementary expertise and resources, accelerating drug development and commercialization. Such partnerships can also provide non-dilutive funding, reducing the company's reliance on equity financing. The timeline for securing and executing such partnerships is ongoing, with potential benefits realized over the next 3-5 years.
• Expansion into new therapeutic areas: Scholar Rock's expertise in growth factor biology can be applied to develop therapies for other diseases beyond neuromuscular disorders, cancer, and fibrosis. Exploring new therapeutic areas, such as autoimmune diseases or metabolic disorders, could diversify the company's pipeline and reduce its reliance on specific indications. This expansion requires significant investment in research and development, with potential timelines extending from 2030 to 2035. The market size for these new therapeutic areas varies, but represents a long-term growth opportunity for Scholar Rock.

What Opportunities Does SRRK Have?

• Expansion of Apitegromab into additional SMA patient populations
• Advancement of SRK-181 in oncology
• Development of novel therapies for fibrosis
• Strategic partnerships and collaborations

What Threats Does SRRK Face?

• Clinical trial failures
• Regulatory hurdles
• Competition from other therapies
• Patent expirations

What Are SRRK's Competitive Advantages?

• Proprietary technology targeting protein growth factors
• Strong intellectual property portfolio
• Clinical-stage product pipeline
• Collaboration agreements with established pharmaceutical companies

What Does SRRK Do?

Founded in 2012 and headquartered in Cambridge, Massachusetts, Scholar Rock Holding Corporation is a biopharmaceutical company dedicated to discovering and developing innovative medicines for the treatment of serious diseases where protein growth factor signaling plays a crucial role. The company's approach centers on targeting these growth factors to address diseases with significant unmet medical needs. Their lead product candidate, Apitegromab, is an inhibitor of myostatin activation and has completed Phase 3 clinical trials for spinal muscular atrophy (SMA). Apitegromab aims to improve motor function in SMA patients by inhibiting myostatin, a protein that limits muscle growth. In addition to Apitegromab, Scholar Rock is developing SRK-181, currently in Phase 1 clinical trials, for the treatment of cancers resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibodies. SRK-181 targets the transforming growth factor beta (TGFβ) pathway, which can suppress the immune system's ability to fight cancer. Scholar Rock also has a pipeline of novel product candidates targeting neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases, expanding their reach in addressing complex diseases. Scholar Rock's focus on growth factor biology and its pipeline of clinical-stage and preclinical programs position it as a company aiming to transform the treatment landscape for a range of severe conditions.

What Products and Services Does SRRK Offer?

• Develop medicines for diseases where protein growth factors play a role
• Focus on neuromuscular disorders, cancer, and fibrosis
• Develop Apitegromab for the treatment of spinal muscular atrophy (SMA)
• Develop SRK-181 for the treatment of cancers resistant to checkpoint inhibitors
• Collaborate with Gilead Sciences on fibrosis treatments
• Discover and develop specific inhibitors of transforming growth factor beta activation

How Does SRRK Make Money?

• Develop and commercialize proprietary therapeutics
• Generate revenue through product sales upon regulatory approval
• Collaborate with other companies for research and development funding
• Out-license intellectual property for additional revenue streams

What Industry Does SRRK Operate In?

Scholar Rock operates within the biotechnology industry, a sector characterized by high risk and high reward. The industry is driven by innovation and the development of novel therapies for unmet medical needs. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share in specific therapeutic areas. Scholar Rock's focus on growth factor-targeted therapies differentiates it from competitors, but it also faces challenges in navigating regulatory hurdles and securing funding for research and development. The biotechnology industry is experiencing growth, driven by advances in genomics, proteomics, and other technologies.

Who Are SRRK's Key Customers?

• Patients with spinal muscular atrophy (SMA)
• Patients with cancers resistant to checkpoint inhibitors
• Patients with fibrotic diseases
• Healthcare providers who prescribe their medications

Scholar Rock Holding Corporation (SRRK) Valuation Context

Valued at $6.19B, SRRK is classified as a mid-cap stock. Relative to its peer group, SRRK's quantitative score of 45/100 is roughly in line with the peer average of 44/100.

Key Financial Metrics

Return on assets is -76.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.64 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.2%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

Scholar Rock Holding Corporation's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 9.42 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Scholar Rock Holding Corporation revenue of about $6.3M for fiscal 2026, with EPS near $-3.16. The estimate reflects 12 contributing analysts.

SRRK Financials

SRRK Latest News

SRRK Analyst Consensus

SRRK MoonshotScore

Latest Scholar Rock Holding Corporation Analysis

SRRK Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources